DBV Technologies (DBVT) Assets Average (2016 - 2026)
DBV Technologies (DBVT) posted Assets Average of $244.8 million for Q2 2026, down 2.1% sequentially from $250.0 million in Q1 2026, and up 152.38% YoY from $97.0 million in Q2 2025.
Analysis
DBV Technologies (DBVT) Assets Average (2016 - 2026) Analysis & Trends
DBV Technologies has reported Assets Average for 10 years, with the latest figure at $244.8 million in Q2 2026.
- Quarterly Assets Average rose 152.38% year-over-year to $244.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $244.8 million (up 152.38% YoY) and the FY2025 annual result came in at $149.7 million, up 20.4% from the prior year.
- Assets Average fell to $244.8 million in Q2 2026 per DBVT's latest filing, from $250.0 million in the prior quarter.
- Over five years, Assets Average peaked at $266.5 million in Q3 2022 and troughed at $58.1 million in Q1 2025.
- A 5-year average of $173.8 million and a median of $179.2 million in 2023 frame the typical range for Assets Average.
- The sharpest annual moves came in 2025 and 2026: Assets Average slumped 64.66% in 2025, then soared 330.3% in 2026.
- Over 5 years, Assets Average stood at $247.3 million in 2022, then slipped by 24.64% to $186.4 million in 2023, then plunged by 57.42% to $79.4 million in 2024, then surged by 116.87% to $172.1 million in 2025, then surged by 42.24% to $244.8 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $244.8 million, $250.0 million, and $172.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 10 | DBV Technologies | 5.88 Bn | 5.70 Bn | - | 244.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 244.80 Mn |
| Mar 31, 2026 | 250.05 Mn |
| Dec 31, 2025 | 172.10 Mn |
| Sep 30, 2025 | 126.96 Mn |
| Jun 30, 2025 | 97.00 Mn |
| Mar 31, 2025 | 58.11 Mn |
| Dec 31, 2024 | 79.36 Mn |
| Sep 30, 2024 | 103.62 Mn |
| Jun 30, 2024 | 130.04 Mn |
| Mar 31, 2024 | 164.44 Mn |
| Dec 31, 2023 | 186.38 Mn |
| Sep 30, 2023 | 203.65 Mn |
| Jun 30, 2023 | 225.22 Mn |
| Mar 31, 2023 | 239.72 Mn |
| Dec 31, 2022 | 247.32 Mn |
| Sep 30, 2022 | 266.55 Mn |
| Jun 30, 2022 | 201.28 Mn |
| Mar 31, 2022 | 132.15 Mn |
| Dec 31, 2021 | 158.82 Mn |
| Sep 30, 2021 | 185.75 Mn |